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ABSTRACT
The role of ’stand- alone’ coronary angiography (CAG) 
in the management of patients with chronic coronary 
syndromes is the subject of debate, with arguments for 
its replacement with CT angiography on the one hand 
and its confinement to the interventional cardiac catheter 
laboratory on the other. Nevertheless, it remains the 
standard of care in most centres. Recently, computational 
methods have been developed in which the laws of 
fluid dynamics can be applied to angiographic images to 
yield ’virtual’ (computed) measures of blood flow, such 
as fractional flow reserve. Together with the CAG itself, 
this technology can provide an ’all- in- one’ anatomical 
and functional investigation, which is particularly 
useful in the case of borderline lesions. It can add to 
the diagnostic value of CAG by providing increased 
precision and reduce the need for further non- invasive 
and functional tests of ischaemia, at minimal cost. In 
this paper, we place this technology in context, with 
emphasis on its potential to become established in the 
diagnostic workup of patients with suspected coronary 
artery disease, particularly in the non- interventional 
setting. We discuss the derivation and reliability of 
angiographically derived fractional flow reserve (CAG- 
FFR) as well as its limitations and how CAG- FFR could 
be integrated within existing national guidance. The 
assessment of coronary physiology may no longer be the 
preserve of the interventional cardiologist.
INTRODUCTION: CORONARY ANGIOGRAPHY 
(CAG) IN THE 2020S
Chronic coronary artery disease (CAD) remains 
a significant healthcare burden fuelled by greater 
longevity, increased expectations and high- quality 
management of acute coronary syndromes. In the 
UK, the National Institute for Health and Care 
Excellence guidelines recommend that CT coro-
nary angiography (CTCA) should be offered as 
the first- line investigation for the investigation of 
stable chest pain.1 According to current activity, 
this would require an eightfold increase in national 
service provision.2 Approximately 250 000 CAGs, 
including about 40 000 in non- interventional 
cardiac catheter laboratories (CCLs), are carried 
out in the UK per annum, a consistent figure in 
recent years.3 The impact of CTCA on this figure is 
as yet unclear. Some have suggested that the rise in 
popularity, accuracy and accessibility of CTCA may 
signal the death knell for CAG,4 yet data reveal a 
slow increase in numbers.3 The main problem with 
CAG is its invasive nature, although radial artery 
access, small diameter catheters and improved 
X- ray contrast medium have reduced the compli-
cation rate to negligible levels. Its main diagnostic 
deficiencies include its anatomical rather than func-
tional nature, a poor relationship between per cent 
stenosis and blood flow, the subjectivity of visual 
interpretation particularly in intermediate (30%–
70%) stenoses5 and technical inadequacies, such 
as poor vessel opacification and lesion assessment. 
Nevertheless, CAG remains the final common 
pathway for revascularisation and treatment plan-
ning and is a prerequisite for valve surgery and other 
major interventions, such as organ transplantation. 
It is often performed in CCLs, which lack the capa-
bility to assess coronary blood flow. Figure 1 illus-
trates the major milestones in its evolution.
FRACTIONAL FLOW RESERVE (FFR)
Coronary blood flow has to adapt to the demands 
of exercise, which is achieved by reduction in the 
coronary microvascular resistance. Maximum 
flow (hyperaemia) is limited by the presence of an 
epicardial coronary stenosis and impaired micro-
vascular function.6 Direct measurement of coro-
nary blood flow is difficult, and the best and most 
widely used surrogate is FFR, the ratio of distal 
to proximal translesional pressure, measured with 
a pressure- sensitive wire during maximum hyper-
aemia, which is usually induced with an infusion 
of adenosine. It represents the maximally achiev-
able flow in a stenotic artery as a percentage of 
the maximum flow expected in the hypothetical 
absence of that stenosis.6 A significant impairment 
of hyperaemic flow is defined as ≥20% reduction, 
that is, FFR≤0.80. FFR was originally validated 
against standard non- invasive tests of ischaemia 
and the threshold for treatment eventually settled 
at ≤0.80.7
What does FFR mean?
There is a considerable evidence base and a class 1a 
recommendation for using FFR, or related indices, 
to guide percutaneous revascularisation.8 This is 
because most of the evidence for the benefit of 
FFR is derived from the interventional rather than 
the initial stage of management, partly because a 
pressure wire is, in fact, a modified angioplasty 
guidewire.6 Using FFR to limit percutaneous coro-
nary intervention (PCI) to lesions with FFR of 
≤0.80 reduces morbidity and inappropriate revas-
cularisation, with attendant economic benefit, 
compared with angiographic guidance alone.9–11 
However, FFR is a continuous variable, so the 0.80 
threshold is only the optimal trade- off between 
sensitivity and specificity at a population level.12 
At the extremes of FFR (severely stenosed vs 
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decision- making, corresponding with the greatest prognostic 
and symptomatic benefits, but diagnostic certainty falls to 50% 
at FFR 0.80.13 FFR is, of course, most useful in the mid- zone in 
cases with moderate stenosis.14 In the landmark trials, however, 
the mean FFR was 0.56–0.68, which is considerably lower than 
this.9 10 Also, there are many factors to be considered when 
intervening on a lesion, such as its complexity, the size and 
quality of the distal vessel, the extent of myocardium at risk, 
other disease and the likely benefit, so decision- making tends 
to incorporate the FFR (or computed FFR) rather than rely on 
it entirely.12
How does FFR affect contemporary clinical decision-making?
The RIPCORD (Does routine pressure wire assessment influence 
management strategy at coronary angiography for diagnosis of 
chest pain?) study was a UK- based, multicentre, prospective, 
randomised controlled trial investigating whether incorpo-
rating routine FFR measurement at diagnostic angiography 
in the assessment of stable CAD would result in a change in 
management compared with angiographic assessment alone. 
The primary endpoint was the difference in management plan 
per coronary artery between the one made using the angiogram 
alone versus after disclosure of the FFR. Two hundred and 
three patients were randomised. There was a change in manage-
ment plan after FFR was disclosed in 53 (26%) patients, and 
the number and location of significant stenoses changed in 64 
(32%). Of 72 cases in which optimal medical therapy (OMT) 
was initially recommended after CAG, nine (13%) were phys-
iologically significant at FFR and were therefore referred for 
revascularisation. Conversely, of 89 cases in whom the manage-
ment plan was OMT based on FFR, revascularisation would 
have been recommended in 25 (28%) based on CAG only.15 
Similar influences of FFR on angiographic decision- making were 
also observed in the setting of acute coronary syndromes in the 
FAMOUS- NSTEMI (Fractional flow reserve vs angiography in 
guiding management to optimize outcomes in non- ST- segment 
Figure 1 Milestones in the history of diagnostic coronary 
angiography. 2D, two- dimensional; FFR, fractional flow reserve; IVUS, 
intravascular ultrasound; OCT, optical coherence tomography; Pa, aortic 
pressure; Pd, pressure distal to stenosis; QCA, quantitative coronary 
angiography. DICOM, Digital Imaging and Communications in Medicine
Figure 2 Principal steps in a CAG- FFR workflow. Step 1: 
optimal views of the lesion are selected with minimal overlap and 
foreshortening, good opacification, during end diastole, greater than 
30° apart; step 2: luminal edge detection and segmentation with 
3D reconstruction; step 3: personalised boundary conditions are 
applied for CFD simulation; step 4: the simulation results are viewed 
in an interactive graphical user interface providing coregistration of 
physiology at every point along the modelled anatomy. CAG- FFR, 
angiographically derived fractional flow reserve; CFD, computational 
fluid dynamic; FFR, fractional flow reserve.
Figure 3 Examples of coronary angiography (left) with corresponding 
‘virtual’ FFR results (right). Standard LAO- caudal projection of a distal 
left circumflex stenosis (*) (A) and VIRTUheart output (B) demonstrating 
a physiologically significant angiography- derived FFR of 0.75. LAO 
projection of a mid right coronary stenosis (*) (C) and VIRTUheart 
output (D) demonstrating a physiologically non- significant angiography- 
derived FFR of 0.94. Aortic pressure projection of a mid left anterior 
descending artery stenosis (*) (E) and VIRTUheart output demonstrating 
an angiography- derived FFR of 0.67 (F), indicating an ischaemia causing 
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elevation myocardial infarction) study, which reported a change 
in management strategy in 21.6% of patients, resulting in fewer 
procedures and unplanned revascularisations.16 These studies 
underline the importance of physiological guidance in everyday 
contemporary practice at the time of CAG.
CORONARY ARTERY BYPASS SURGERY (CABG): A MAJOR 
UNMET NEED FOR PHYSIOLOGICAL GUIDANCE
The patients most deserving of physiological guidance are 
those with multivessel disease being considered for CABG.17 
However, very few receive pressure wire assessment prior 
to CABG, and often, referral for surgery is based on a CAG 
performed in a non- interventional CCL. Further guidance with 
FFR would require a second visit to a CCL, with associated 
delays, and is therefore rarely done. Without FFR, if two vessels 
need grafting, the third being angiographically borderline, the 
surgeon may feel obliged to apply a graft which, if the lesion is 
physiologically insignificant, may lead to an unnecessarily long 
operation, a wasted conduit, and occlusion due to competitive 
flow. Anatomical triple vessel disease, ‘mandating’ CABG, when 
subjected to physiological assessment, may be converted to phys-
iological two- or even one- vessel disease, adequately treated by 
PCI. This was described in a subanalysis of the SYNTAX (Taxus 





(%) Specificity (%) PPV (%) NPV (%) AUC Patients (n)
Correlation with 
FFR
BA limits of 
agreement
Morris et al24 vFFR 97 86 100 100 97 * 19 0.84 FFR±0.16
Tröbs et al30 FFRangio 90 79 94 85 92 0.93 73 0.85 FFR±0.13
Tu et al27 QFR 88 78 93 82 91 0.93 68 0.81 FFR±0.13
Papafaklis et al29 vFAI 88 90 86 80 94 0.92 120 0.78 *
Pellicano et al31 FFRangio 93 88 95 22† 0.12† 0.97 184 0.90 FFR±0.10
Kornowski et al32 FFRangio 94 88 98 * * * 88 0.90 FFR±0.10
Xu et al33 QFR 92 95 92 86 97 0.96 308 0.86 FFR±0.13
Yazaki et al34 QFR 89 89 88 74 95 0.93 142 0.80 FFR±0.10
Westra et al28 QFR 83 77 86 75 87 0.86 172 0.70 FFR±0.12
Fearon et al35 FFRangio 92 94 91 89 95 0.80 301 0.80 FFR±0.13
Omori et al36 FFRangio 92 92 92 * * 0.92 50 0.83 FFR±0.14
Stähli et al37 QFR 93 75 98 89 94 0.86 436 0.82 FFR±0.07
Li et al38 caFFR 96 90 99 97 95 0.98 328 0.89 FFR±0.10
*Not reported.
†Likelihood ratio reported.
AUC, area under the receiver operating curve; BA, Bland- Altman; caFFR, FlashAngio Rainmed, China; FFR, fractional flow reserve; FFRangio, CathWorks, Israel; NPV, negative predictive value; PPV, positive predicted 
value; QFR, quantitative flow ratio; vFAI, CAAS 3D- QCA, Pie Medical Imaging, Netherlands; vFFR, VIRTUheart, University of Sheffield, UK.
Table 2 Comparison of CTCA with invasive CAG
Factor CTCA Invasive CAG
Invasiveness Non- invasive Invasive
Cost (£) 305* 2000*
Radiation dose (mSv) 2–5 2–12
Contrast dose (mL) 50–120 13–90
Spatial resolution (mm) 0.50 0.16
Temporal resolution (ms) 83–153 1–10
Sensitivity for obstructive 
CAD
High Gold- standard investigation
Specificity for obstructive 
CAD
Low to moderate Gold- standard investigation






Other limiting factors Intolerance of rate- limiting 
medication
Motion artefacts
Intolerance of hyperaemia- 
inducing medication
Physiological adjuncts FFRCT Invasive FFR/iFR/CFR
CAG- FFR
Complication rate Contrast- induced anaphylaxis 
<1%
Contrast- induced nephropathy 
3%
Side effects related to rate- 
limiting medications uncommon
Arterial access site complications 
(radial) 0.2%
Major adverse events (MI 0.05%, 
CVA 0.07%, death 0.08%)
Contrast- induced anaphylaxis 
<1%
Contrast- induced nephropathy 
3%
*Average cost of a standard outpatient NHS study.
CAD, coronary artery disease; CAG, coronary angiography; CAG- FFR, angiographically derived fractional 
flow reserve; CTCA, CT coronary angiography; CVA, cerebrovascular accident; eGFR, estimated 
glomerular filtration rate; FFR, fractional flow reserve; FFRCT, computed tomography derived fractional 
flow reserve; iFR, instantaneous wave- free ratio; MI, myocardial infarction.
Box 1 Standardised angiography protocol to maximise 
the applicability of angiographically derived fractional 
flow reserve
General measures
 ► Administer Glyceryl trinitrate prior to acquisition to minimise 
spasm.
 ► Centre the image before acquiring.
 ► Minimal magnification (mag) (+1 mag only if small patient).
 ► Minimise table movement ('panning').
 ► Increase X- ray dose if the patient is obese.
 ► Good catheter engagement.
 ► Good opacification of the vessel.
 ► Acquisition over at least four cardiac cycles.
 ► Minimal adjustment of table height between runs.
 ► Ensure ECG signal is captured (for ECG gating in some 
systems).
Suggested RCA views
 ► LAO cranial.
 ► PA cranial.
 ► RAO cranial.
Suggested LCA views
 ► PA caudal
 ► RAO caudal.
 ► PA cranial
 ► LAO caudal (40°/40°).
Ensure good separation between projections (at least 30°), good visual-
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drug- eluting stent versus coronary artery bypass surgey for the 
treatment of narrowed arteries) II trial in which only 37.2% of 
patients remained being classified as having triple vessel disease 
after invasive physiological assessment.18 This group of patients 
may derive particular benefit from angiography- derived FFR 
(FFR computed from the angiogram). Although clinical trials 
comparing physiology- guided CABG with angiography- guided 
CABG have not shown clear benefit of physiological guid-
ance, these trials included small numbers of patients, and it 
seems counterintuitive to graft a vessel with non- flow- limiting 
disease.19 Retrospective analysis of the major revascualrisation 
trials using CAG- FFR is limited due to the lack of a specific 
acquisition protocol required to fulfil all the technical require-
ments of CAG- FFR analysis.20
WHY IS FFR SO RARELY EMPLOYED?
In view of the universally beneficial influence of FFR in CAD, it 
is surprising that its use, even in the setting of PCI, is so sparse.5 
The reasons are relevant to the future uptake of angiography- 
derived FFR. First, measured physiology, requiring a pressure 
wire, is a necessity, performed only in interventional CCLs, and 
36% of UK CCLs are non- interventional.3 Second, the skill set, 
time and equipment must be available to do it. Third, there is a 
significant upfront cost for each pressure wire. Finally, there are 
reasons summarised as ‘professional judgement’, where physi-
cians wrongly perceive that they can make the right decisions 
without the use of physiology.5 The solution may lie in the avail-
ability of computational physiology by default, alongside the 
anatomical imaging.
WHAT IS ANGIOGRAPHICALLY DERIVED FRACTIONAL FLOW 
RESERVE (CAG-FFR)?
CAG- FFR is calculated from medical images of the coronary 
artery using the physical laws governing fluid flow. The vessel 
geometry is constructed from either standard CTCA21–23 or 
invasive CAG.24 The flow through the reconstructed artery 
is determined not only by the stenosis geometry but also by 
boundary conditions that represent the physiological conditions 
at the inlet, outlets and vessel wall. These can be prescribed 
to simulate hyperaemic or resting flow conditions. The selec-
tion of boundary conditions is an accuracy- defining step.24 
The CTCA system (HeartFlow Inc, Redwood City, California, 
USA) is already impacting clinical practice and can be used to 
improve the role of CTCA as a gatekeeper for CAG, especially 
when CTCA shows CAD with uncertain functional signifi-
cance.1 However, its availability only as a core laboratory service 
(HeartFlow, Redwood City, California, USA), lower specificity 
compared with invasive physiological assessment and image 
limitations (see further) represent its main limitations.25 26 A 
variety of systems that compute angiography- derived FFR 
from CAG using different methodologies are now available. 
Figure 2 outlines the basic workflow of CAG- FFR calculation. 
The computational time has been reduced to minutes or even 
seconds, making these systems viable in the CCL. The first of 
these was the VIRTUheart software developed by the Univer-
sity of Sheffield, employing computational fluid dynamic (CFD) 
modelling to calculate FFR.24 Commercially available systems 
now include quantitative flow ratio (QFR) (Medis, Leiden, 
Netherlands, and Pulse Medical Imaging Technology, Shanghai, 
China), FFRangio (CathWorks, Kfar- Sba, Israel) and CAAS QCA 
3D (Pie Medical, Maastricht, Netherlands), which use 3D QCA 
with mathematical modelling to compute coronary lesion signif-
icance. Examples of CAG- FFR results are shown in figure 3.
Can we rely on CAG-FFR?
To assess CAG- FFR, we must first consider the accuracy of 
measured FFR because FFR is a surrogate for flow reserve, 
and CAG- derived FFR is therefore a ‘surrogate of a surrogate’. 
Table 1 summaries the diagnostic parameters of CAG- FFR from 
major trials.24 27–38 The first difficulty is that FFR is the best tool 
we have and there is no better test with which to compare it. 
Second, poor technique can adversely affect its accuracy. It is 
important that the catheter is not ‘plugged’ in the artery; the 
wire position is appropriate and stable; and the value recorded 
is during plateau (stable) hyperaemia. Third, there is variability 
between repeat measurements, even in the best hands, driven by 
biological variation. As with other tests of ischaemia, CAG- FFR 
is assessed against measured FFR, with the limitations outlined 
Figure 4 Proposed algorithm for the diagnostic pathway of suspected 
CAD integrating CTFFR and CAG- FFR. CAD, coronary artery disease; 
CAG, coronary angiography; CMR, cardiac MRI; CTCA, CT coronary 
angiography; CTFFR, CT fractional flow reserve; FFR, FFR, fractional 
flow reserve; OMT, optimal medical therapy; PCI, percutaneous coronary 
intervention; SPECT, single- photon emission. DSE, dobutamine stress 
echocardiography.
Box 2 Summary of key points
What do we already know?
 ► Despite non- invasive investigations, invasive coronary 
angiography (CAG) remains the final common investigation 
for all patients under assessment for revascularisation.
 ► Visual assessment of stenosis severity is subjective and its 
relationship to ischaemia is unreliable.
 ► FFR is the gold standard for invasive ischaemia testing, but is 
under-used.
Key learning points:
 ► Some systems of ‘virtual’ FFR, based on invasive CAG, are 
now approved for clinical use and could provide an ‘all- in- 
one’ test for coronary artery disease.
 ► The accuracy of CAG- FFR depends on good quality image 
acquisition and optimal technique.
 ► CAG- FFR can be integrated into existing cardiac catheter 
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earlier. CAG- FFR is not subject to any of the technical limitations 
of directly measured FFR, but its accuracy is poorest around the 
threshold of treatment (0.80). The accuracy of CAG- FFR is, 
however, related to the accuracy of the reconstruction (influ-
enced by the quality of CAG) and to assumptions made in the 
mathematics applied in the computation of FFR. In the FAVOR 
(Diagnostic performance of in- procedure- angiography- derived 
quantitative flow reserve compared to pressure- derived frac-
tional flow reserve) II study, the accuracy of QFR (vs measured 
FFR) was 71.3% between FFR values of 0.75 and 0.84.28 For 
comparison, the accuracy of CTFFR in the zone 0.70–0.80 is 
only 46.1%.39 The overall limits of agreement (akin to a 95% 
CI) for CAG- FFR and CTFFR are similar at ±0.14 and ±0.15, 
respectively. In the context of the clinical range of FFR (0.50–
1.00), a CI of ±0.14 is relatively poor,40 especially for lesions 
close to the threshold. Such cases may require a further test of 
ischaemia, and ideally a directly measured FFR, with the possi-
bility of follow- on PCI. Finally, its performance and accuracy 
in the hands of operators who are not CFD- modelling experts, 
beyond special interest research centres, are yet to be established.
What are the advantages of CAG-FFR?
CAG- FFR is an ideal all- in- one test for patients being assessed 
for revascularisation, particularly for those triaged directly for 
invasive CAG. CAG- FFR could provide enhanced and rapid 
decision- making while the patient is on the table. Its great advan-
tage is that it can provide a preliminary physiological assessment 
in any CAG, including in non- tertiary centres, without the need 
of a wire, an interventionist, extra equipment or expense. This 
represents a substantially increased potential compared with the 
present situation. In the UK, for example, of the annual 250 
000 CAGs, only about 13 000 include pressure wire assessment, 
all of which are in interventional CCLs, and of the 100 000 
PCIs performed, only 10 000 involve pressure wire assessment.3 
Therefore, of all patients assessed and treated, invasive physi-
ology is deployed in only 6%–7%. The availability of CAG- FFR 
is likely to considerably increase the availability of coronary 
physiology, wherever a CAG be performed, with a reduction in 
subsequent non- invasive tests of ischaemia, delays and further 
visits to the CCL. If performed in an interventional CCL, it can 
justify proceeding to PCI immediately but, importantly, deferring 
it in others. The software licences for CAG- FFR means the per- 
patient price will likely be low and, being software- based, can be 
integrated into existing CCLs relatively simply. CAG- FFR may 
also enable advanced treatment planning by simulating the phys-
iological effects of virtual stent deployment. This, in turn, could 
help operators to achieve optimal physiological benefit while 
minimising the length of the stent deployed.41 Ultimately, the 
CFD methods behind CAG- FFR may also enable quantification 
of absolute (volumetric) blood flow and other parameters, such 
as microvascular resistance, providing a more comprehensive 
coronary physiological assessment.42 In the future, intravascular 
ultrasound and optical coherence tomography, coregistered with 
CAG, may augment anatomical reconstruction, and this may 
improve CAG- FFR accuracy.
How does CAG-FFR compare with other tests of ischaemia?
When invasively measured FFR was introduced, it was validated 
against the accepted tests of the day: exercise testing, thallium 
single- photon emission CT (SPECT) and stress echocardiog-
raphy.8 Since then, stress perfusion cardiac MRI (CMR) has 
become established as superior to SPECT.43 In the CE- MARC 
trial, FFR was used as the reference standard, against which 
perfusion MRI was assessed.43 So, when CAG- FFR is assessed 
against SPECT, there is a degree of discordance, but, compared 
with perfusion CMR, its accuracy is 92%.44 It is important to 
appreciate the differences between these tests. The main one 
is that CMR is an excellent test of the overall and regional 
burden of ischaemia, whereas FFR addresses the contribution 
of a specific lesion in a particular artery. The other is that FFR, 
while being accurate as regards the contribution of the lesion to 
blood flow limitation, provides no information about the state 
of the microvasculature.42 Indeed, disease in this compartment 
may explain some of the ‘false positive’ results of non- invasive 
tests like pMRI when compared with CAG and FFR. Although 
primarily an anatomical test, like CAG, CTCA is the basis of 
CTFFR. Compared with invasive FFR, accuracy is approx-
imately 84%.21 22 The limitations of CTFFR are those of CT 
itself, namely, image resolution (still considerably lower than 
CAG), calcification, atrial fibrillation, tachycardia and motion 
artefact contributing to its wide zone of uncertainty around the 
clinical decision point of 0.80, which is exactly where precision 
is required.39 45 As with FFR, neither CAG- FFR nor CTFFR 
provide information about absolute blood flow or microvascular 
physiology.
What are the limitations of CAG-FFR?
Like CTFFR, CAG- FFR is particularly dependent on the quality 
of the angiographic images. This is because CAG is essentially a 
series of two- dimensional (2D) images that need to be converted 
into a three- dimensional (3D) computational model. Even a 
straight tube with a simple stenosis needs two 2D images, at least 
30 degrees apart, to derive a reasonably accurate 3D model. 
Thus, lesions located at bifurcations, with an overlapping vessel, 
at the arterial ostium or in the left main artery, pose partic-
ular challenges. As with a simple diagnostic CAG, poor cath-
eter engagement, inadequate artery opacification with contrast, 
excessive ‘panning’, movement (patient, respiratory or cardiac), 
magnification or ‘coning’ that obscures or cuts off parts of the 
vessel are problematic. Therefore, as many as 80% of CAGs are 
unsuitable for analysis, but with some simple improvements in 
angiographic technique (box 1), this figure can be substantially 
reduced.46 Centres that have adopted CAG- FFR often report 
improvement in the quality of angiography when working with 
an acquisition protocol suited for CAG- FFR analysis. A level 
of skill in image processing is also required, with knowledge of 
coronary anatomy and training in using the software, particu-
larly at the segmentation step.47 In most centres, this is likely to 
be the domain of the radiographer. The main scientific limitation 
and challenge in these models is that of variability in the resis-
tance of the coronary microvascular bed. Not only is this the 
dominant influence of coronary blood flow and FFR, but also it 
is the single largest contributor to error in CAG- FFR.48 Because 
microvascular resistance is unknown, models rely on assump-
tions which do not apply in all patients, such as those with prior 
MI, diabetes or LVH.49
Where could CAG-FFR fit into future practice?
In the same time frame as physiological assessment became 
acknowledged to be superior to solely anatomical assessment 
of coronary heart disease, UK guidelines changed to advocate 
CTCA, a purely anatomical test. Functional tests of ischaemia 
are recommended in cases in which there is uncertainty about 
the findings of CTCA.1 These same tests are also first- line inves-
tigations in symptomatic patients with confirmed CAD. CAG 
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Pretest stratification according to the likelihood of significant 
CAD often overestimates risk and has fallen out of current 
national guidance.3 European guidance supports the use of CAG 
for patients who have a high pretest probability of CAD with 
significant risk factors and refractory angina or typical angina 
at low workloads,8 a pathway which retains some popularity 
for many cardiologists. Given the characteristics of CTCA and 
CAG (table 2), current uncertainties and the variability of locally 
available investigations, we propose a modified algorithm for 
the diagnosis of obstructive CAD incorporating virtual coro-
nary physiology (figure 4). In this framework, the role of CAG 
is strengthened. Instead of some patients at medium and higher 
risk requiring both a non- invasive test and CAG, they could have 
a stand- alone CAG- FFR providing a detailed and appropriate 
plan for revascularisation in a time- efficient manner. Several 
clinical trials are currently ongoing to evaluate the impact of 
CAG- FFR on clinical outcomes.50
CONCLUSION
The addition of computational modelling of blood flow to a 
standard CAG can provide a detailed and specific ‘all- in- one’ 
combined anatomical and physiological assessment of CAD at a 
low cost. It could help guide decisions about revascularisation, 
streamline management, be a useful gatekeeper to the inter-
ventional laboratory, and triage patients and lesions for direct, 
invasive measurements of FFR and similar indices. The lack of 
requirement for a pressure wire makes this technology feasible 
in the purely diagnostic cardiac catheterisation laboratory, 
providing the benefits of physiological guidance to a far greater 
number of patients with CAD than at present receive it (Box 2). 
Angiography- derived physiology may represent a renaissance for 
invasive CAG.
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